BioPharma Dive reported on Nexo's financing and five-year MD Anderson partnership, framing the company as part of a new wave of startups bringing a more deliberate approach to covalent drug design.
The story also positioned Nexo within the broader financing climate for oncology biotechs and noted that the Series A round is intended to move at least one program toward a drug candidate. It described the MD Anderson collaboration as a way for the company to access tumor models and deep translational expertise without building that capability alone.
BioPharma Dive covered Nexo’s financing and five-year MD Anderson partnership as part of a new wave of startups taking a more deliberate approach to covalent drug design. The article highlighted the company’s focus on moving beyond cysteine-based binding and using its platform to identify compounds against targets that have historically been hard to reach.
Original coverage: BioPharma Dive